Summary
Twenty-five women with advanced breast cancer were treated in a phase II trial of iproplatin 275 mg/m2 administered intravenously every 4 weeks. All patients had measurable or evaluable indicator lesions, and had undergone treatment with no more than one previous chemotherapy regimen, including adjuvant chemotherapy. Two of the twenty-four evaluable patients (8%) experienced major therapeutic responses. One patient had a complete regression of pulmonary nodules lasting 18 + months; another had a partial regression of metastatic disease in the liver (4 months). The inevaluable patient was ineligible for the study because of previous radiation to the indicator lesions on her chest wall; nonetheless, she experienced a 10 month partial regression of those nodules. Myelosuppression was generally dose limiting; thrombocytopenia was more profound, but leukopenia was more prolonged. Nausea, vomiting, diarrhea, and general malaise were prominent toxicities, and led to discontinuation of therapy in 4 patients. Iproplatin has limited activity in previously treated women with advanced breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Forastiere AA, Hakes TB, Wittes JT, Wittes RE: Cisplatin in the treatment of metastatic breast cancer. Am J Clin Oncol (CCT) 5:243–247, 1982
Ostrow S, Egorin M, Aisner J, Bachur N, Wiernick PH: High-dose cis-diamminedichloroplatinum therapy in patients with advanced breast cancer: Pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials 3:23–27, 1980
Kolaric K, Roth A: Phase II clinical trial of cis-dichlordiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11:108–112, 1983
Rossof AH, Slayton RE, Perlia CP: Preliminary clinical experience with cis-diamminedichloroplatinum (II). Cancer 30:1451–1456, 1972
Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH: High dose cisplatinum diamine dichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372–1381, 1977
Catane R, Douglass Jr HO, Mittelman A: A phase II study of high dose cisdiammine dichloroplatinum (CDDP) in non-testicular tumors (Abstr). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 18:115, 1977
Sledge GW Jr, Loehrer PJ Sr, Roth BJ, Einhorn LH: Cisplatin as first-line therapy for metastatic breast cancer (Abstr). Proc Am Soc Clin Oncol 6:53, 1987
Bajorin D, Bosl GJ, Fein R: Phase I trial of escalating doses of cisplatin in hypertonic solution. J Clin Oncol 5:1589–1593, 1987
Lee FH, Canetta R, Issell BF, Lenaz L: New platinum complexes in clinical trials. Cancer Treat Rev 10:39–51, 1983
Ginsberg SJ: CHIP. Phase I study. SUNY Upstate Medical Center. Minutes of the phase II meeting; December 12, 1983; Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Creaven PJ, Madajewicz S, Pendyala L, Mittleman A, Pontes E, Spaulding M, Arbuck S, Solomon J: Phase I clinical trial of cis-dichlor-trans-dihydroxy-bis-isopropylamine platinum (IV) (CHIP). Cancer Treat Rep 67:795–800, 1983
Ribaud P, Gouveia J, Dorval T, Misset JL, Machover D, Gastiaburu J, Schwarzenberg L, Mathe G: Phase I study of CHIP (Abstr). Fourth NCI-EORTC Symp. on New Drugs in Cancer Therapy, 1983
Yap BS, Tenney DM, Yap HY, Plager C, Papadopoulos NE, Lee FH, Issell BF, Bodey GP: Phase I trial of CHIP (Abstr). In: MP Hacker, EB Douple, IH Krakoff (eds). Platinum Coordination Complexes in Cancer Chemotherapy. Martinus Nijhoff, Boston, 1984, p 203
Breast Cancer Task Force, Treatment Committee, National Cancer Institute: Breast Cancer: Suggested Protocol Guidelines for Combined Modality Trials. Washington DC, United States Department of Health Education and Welfare, Publication No (NIH) 77-1192
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Samal B, Vaitkevicius, Singhakowinta A, O'Bryan R, Buroker T, Samson M, Baker LH: Cis-diamminedi-chloroplatinum (CCDP) in advanced breast and colorectal carcinoma (Abstr). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 19:347, 1978
Bull JM, Anderson T, Lippman ME, Cassidy JG, Gormley PE, Young RC: A phase II trial of cis-dichlorodiammine platinum (cis DDP) in breast and ovarian carcinomas (Abstr). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 19:345, 1978
Yap HY, Salem P, Hortobagyi GN, Bodey GP Sr, Buzdar AU, Tashima CK, Blumenschein GR: Phase II study of cisdichlorodiammineplatinum (II) in advanced breast cancer. Cancer Treat Rep 62:405–408, 1978
Vermorken JB, Gundersen S, Smyth JF, Dodion P, Siegenthaler P, Renard J, Pinedo HM: Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer (Abstr). Proc Am Soc Clin Oncol 5:73, 1986
Booth BW, Weiss RB, Korzun AH, Wood WC, Carey RW, Panasci LC: Phase II trial of carboplatin in advanced breast carcinoma: a Cancer and Leukemia Group B study. Cancer Treat Rep 69:919–920, 1985
Meisner D, Ginsberg S, Nicaise C, Ditch A, Louie A, Newman N, Comis R, Poiesz B: A phase II trial of iproplatin (CHIP) in previously treated breast cancer (Abstr). Proc Am Soc Clin Oncol 6:63, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Casper, E.S., Smart, T.C., Hakes, T.B. et al. Clinical trial of iproplatin (cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV, CHIP) in patients with advanced breast cancer. Invest New Drugs 6, 87–91 (1988). https://doi.org/10.1007/BF00195365
Issue Date:
DOI: https://doi.org/10.1007/BF00195365